Eva Kimby

Publications
CV
Public outreach and news

Articles

Article: BONE MARROW TRANSPLANTATION. 2021;56(6):1413-1421
Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial
Pettengell R; Uddin R; Boumendil A; Johnson R; Metzner B; Martin A; Romejko-Jarosinska J; Bence-Bruckler I; Giri P; Niemann CU; Robinson SP; Kimby E; Schmitz N; Dreger P; Goldstone AH; Montoto S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(6):1031-1034
Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy-free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)
Moccia AA; Schaer S; Hayoz S; Pirosa MC; Taverna C; Novak U; Kimby E; Ghielmini M; Zucca E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;191(5):738-747
The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy
Kimby E; Lockmer S; Holte H; Hagberg H; Wahlin BE; Brown P; Ostenstad B
Article: ANNALS OF HEMATOLOGY. 2020;99(10):2357-2366
Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy
Junlen H-R; Lockmer S; Kimby E; Wahlin BE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(4):707-717
Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy
Menter T; Tzankov A; Zucca E; Kimby E; Hultdin M; Sundstrom C; Beiske K; Cogliatti S; Banz Y; Cathomas G; Katjalainen-Lindsberg M-L; Grobholz R; Mazzucchelli L; Sander B; Hawle H; Hayoz S; Dirnhofer S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;188(2):259-267
M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy
Lockmer S; Ren W; Brodtkorb M; Ostenstad B; Wahlin BE; Pan-Hammarstrom Q; Kimby E
Article: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(35):3359-3368
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium
Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn M-H; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D
Article: BLOOD. 2019;134(4):353-362
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Zucca E; Rondeau S; Vanazzi A; Ostenstad B; Mey UJM; Rauch D; Wahlin BE; Hitz F; Hernberg M; Johansson A-S; Brown PDN; Hagberg H; Ferreri AJM; Lohri A; Novak U; Zander T; Bersvendsen H; Bargetzi M; Mingrone W; Krasniqi F; Dirnhofer S; Hayoz S; Hawle H; Vilei SB; Ghielmini M; Kimby E; Caspar C; Koberle D; Novak U; Zenhausern R; Jost LM; Mach N; Voegeli M; Tscherry G; Fischer N; Burkhard R; Schmid M; Panagiotis S; Munksgaard L; Hernberg M; Vasala K; Lehtinen T; Jyrkkio S; Ekanger R; Rolke J; Meyer P; Maisenholder M; Eidem M; Radlund A; Lagerlof I; Brandefors L; Ola LPN; Arnljots K; Kimby E; Strandberg M
Article: HAEMATOLOGICA. 2019;104(4):797-804
FFirst-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
Sylvan SE; Asklid A; Johansson H; Klintman J; Bjellvi J; Tolvgard S; Kimby E; Norin S; Andersson P-O; Karlsson C; Karlsson K; Lauri B; Mattsson M; Sandstedt AB; Strandberg M; Osterborg A; Hansson L
Article: CANCER IMMUNOLOGY RESEARCH. 2019;7(3):355-362
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Josefsson SE; Beiske K; Blaker YN; Forsund MS; Holte H; Ostenstad B; Kimby E; Koksal H; Walchli S; Bai B; Smeland EB; Levy R; Kolstad A; Huse K; Myklebust JH
Article: TURKISH JOURNAL OF HEMATOLOGY. 2019;36:21-25
Follicular Lymphoma - Focus on Therapy
Kimby E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;183(4):564-577
Prognostic factors and primary treatment for Waldenstrom macroglobulinemia - a Swedish Lymphoma Registry study
Brandefors L; Melin B; Lindh J; Lundqvist K; Kimby E
Article: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(33):JCO1800262-3323
Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up
Lockmer S; Ostenstad B; Hagberg H; Holte H; Johansson A-S; Wahlin BE; Wader KF; Steen CB; Meyer P; Maisenholder M; Smedby KE; Brown P; Kimby E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;183(2):212-224
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes
Palma M; Krstic A; Perez LP; Bergloef A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Hoeglund P; Kimby E; OEsterborg A; Mansson R; Smith CIE
Article: ANNALS OF ONCOLOGY. 2018;29(Suppl 4):iv41-iv50
Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Kastritis E; Leblond V; Dimopoulos MA; Kimby E; Staber P; Kersten MJ; Tedeschi A; Buske C
Article: BLOOD. 2018;132(9):892-902
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies
Dreger P; Ghia P; Schetelig J; van Gelder M; Kimby E; Michallet M; Moreno C; Robak T; Stilgenbauer S; Montserrat E
Article: LANCET HAEMATOLOGY. 2018;5(8):e359-e367
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
Federico M; Caballero Barrigon MD; Marcheselli L; Tarantino V; Manni M; Sarkozy C; Alonso-Alvarez S; Wondergem M; Cartron G; Lopez-Guillermo A; Issa D; Morschhauser F; Alcoceba M; Kimby E; Rusconi C; Chamuleau M; Holte H; Lockmer S; Montoto S; da Silva MG; Aurer I; Zucca E; Paszkiewicz-Kozik E; Minoia C; Skrypets T; Blaker YN; Salles G; Coiffier B
Article: VACCINE. 2018;36(25):3701-3707
Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group
Svensson T; Kattstrom M; Hammarlund Y; Roth D; Andersson P-O; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
Article: LEUKEMIA & LYMPHOMA. 2017;58(10):2356-2362
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia
Vojdeman FJ; Herman SEM; Kirkby N; Wiestner A; van t' Veer MB; Tjonnfjord GE; Itala-Remesg MA; Kimby E; Farooqui MZ; Polliack A; Wu KL; Doorduijn JK; Alemayehu WG; Wittebol S; Kozak T; Walewski J; Abrahamse-Testroote MCJ; Van Oers MHJ; Geisler CH; Niemann CU
Article: HAEMATOLOGICA. 2017;102(8):1413-1423
Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium
Stevens WBC; Mendeville M; Redd R; Clear AJ; Bladergroen R; Calaminici M; Rosenwald A; Hoster E; Hiddemann W; Gaulard P; Xerri L; Salles G; Klapper W; Pfreundschuh M; Jack A; Gascoyne RD; Natkunam Y; Advani R; Kimby E; Sander B; Sehn LH; Hagenbeek A; Raemaekers J; Gribben J; Kersten MJ; Ylstra B; Weller E; de Jong D
Article: VACCINE. 2017;35(14):1764-1769
Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies
Parrino J; McNeil SA; Lawrence SJ; Kimby E; Pagnoni MF; Stek JE; Zhao Y; Chan ISF; Kaplan SS
Article: LEUKEMIA & LYMPHOMA. 2017;58(3):594-600
The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia
Vojdeman FJ; van't Veer MB; Tjonnfjord GE; Itala-Remes M; Kimby E; Polliack A; Wu KL; Doorduijn JK; Alemayehu WG; Wittebol S; Kozak T; Walewski J; Abrahamse-Testroote MCJ; van Oers MHJ; Geisler CH
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2017;23(3):428-435
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Gronbaek K; Jerkeman M; Laurell A; Raty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundstrom C; Ehinger M; Karjalainen-Lindsberg M-L; Delabie J; Ralfkiaer E; Fagerli U-M; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH
Article: ANNALS OF HEMATOLOGY. 2017;96(2):253-259
Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
Cheson BD; Trask PC; Gribben JG; Dimier N; Kimby E; Lugtenburg PJ; Thieblemont C; Wassner-Fritsch E; Launonen A; Sehn LH
Article: HAEMATOLOGICA. 2017;102(1):43-51
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome
Minnema MC; Kimby E; D'Sa S; Fornecker L-M; Poulain S; Snijders TJ; Kastritis E; Kremer S; Fitsiori A; Simon L; Davi F; Lunn M; Castillo JJ; Patterson CJ; Le Garff-Tavernier M; Costopoulos M; Leblond V; Kersten M-J; Dimopoulos MA; Treon SP
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2016;175(3):410-418
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
Eskelund CW; Kolstad A; Jerkeman M; Raty R; Laurell A; Eloranta S; Smedby KE; Husby S; Pedersen LB; Andersen NS; Eriksson M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundstrom C; Delabie J; Karjalainen-Lindsberg M-L; Workman CT; Garde C; Elonen E; Brown P; Gronbaek K; Geisler CH
Article: EXPERT REVIEW OF CLINICAL IMMUNOLOGY. 2016;12(9):921-926
Prophylactic immunoglobulin therapy in secondary immune deficiency - an expert opinion
Agostini C; Blau I-W; Kimby E; Plesner T
Article: ACTA ONCOLOGICA. 2016;55(1):91-98
Familial Waldenstrom's macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies - A population-based study from northern Sweden
Brandefors L; Kimby E; Lundqvist K; Melin B; Lindh J
Article: LEUKEMIA & LYMPHOMA. 2015;56(9):2598-2607
Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas
Kimby E; Ostenstad B; Brown P; Hagberg H; Erlanson M; Holte H; Linden O; Johansson A-S; Ahlgren T; Wader K; Wahlin BE; Delabie J; Sundstrom C
Article: LANCET. 2015;385(9980):1873-1883
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
Hillmen P; Robak T; Janssens A; Babu KG; Kloczko J; Grosicki S; Doubek M; Panagiotidis P; Kimby E; Schuh A; Pettitt AR; Boyd T; Montillo M; Gupta IV; Wright O; Dixon I; Carey JL; Chang C-N; Lisby S; McKeown A; Offner F
Article: HAEMATOLOGICA. 2015;100(4):511-516
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia
Moreno C; Montillo M; Panayiotidis P; Dimou M; Bloor A; Dupuis J; Schuh A; Norin S; Geisler C; Hillmen P; Doubek M; Trneny M; Obrtlikova P; Laurenti L; Stilgenbauer S; Smolej L; Ghia P; Cymbalista F; Jaeger U; Stamatopoulos K; Stavroyianni N; Carrington P; Zouabi H; Leblond V; Gomez-Garcia JC; Rubio M; Marasca R; Musuraca G; Rigacci L; Farina L; Paolini R; Pospisilova S; Kimby E; Bradley C; Montserrat E
Article: ONCOGENE. 2015;34(10):1231-1240
High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma
Kuo P-Y; Leshchenko VV; Fazzari MJ; Perumal D; Gellen T; He T; Iqbal J; Baumgartner-Wennerholm S; Nygren L; Zhang F; Zhang W; Suh KS; Goy A; Yang DT; Chan W-C; Kahl BS; Verma AK; Gascoyne RD; Kimby E; Sander B; Ye BH; Melnick AM; Parekh S
Article: LEUKEMIA. 2015;29(3):668-676
Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study
Junlen HR; Peterson S; Kimby E; Lockmer S; Linden O; Nilsson-Ehle H; Erlanson M; Hagberg H; Radlund A; Hagberg O; Wahlin BE
Article: LEUKEMIA. 2015;29(2):464-473
The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma
Robinson S; Dreger P; Caballero D; Corradini P; Geisler C; Ghielmini M; Le Gouill S; Kimby E; Rule S; Vitolo U; Dreyling M; Hermine O
Article: BLOOD. 2014;124(26):3841-3849
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Dreger P; Schetelig J; Andersen N; Corradini P; van Gelder M; Gribben J; Kimby E; Michallet M; Moreno C; Stilgenbauer S; Montserrat E
Article: CLINICAL CANCER RESEARCH. 2014;20(23):6096-6104
T-Cell Levels Are Prognostic in Mantle Cell Lymphoma
Nygren L; Wasik AM; Baumgartner-Wennerholm S; Jeppsson-Ahlberg A; Klimkowska M; Andersson P; Buhrkuhl D; Christensson B; Kimby E; Wahlin BE; Sander B
Article: ONCOSCIENCE. 2014;1(8):550-557
Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features.
Wasik AM; Nygren L; Almestrand S; Zong F; Flygare J; Wennerholm SB; Saft L; Andersson P; Kimby E; Wahlin BE; Christensson B; Sander B
Article: EPIGENETICS. 2014;9(6):910-917
microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia
Deneberg S; Kanduri M; Ali D; Bengtzen S; Karimi M; Qu Y; Kimby E; Mansouri L; Rosenquist R; Lennartsson A; Lehmann S
Article: BLOOD. 2014;123(21):3255-3262
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL
Geisler CH; vant' Veer MB; Jurlander J; Walewski J; Tjonnfjord G; Remes MI; Kimby E; Kozak T; Polliack A; Wu KL; Wittebol S; Abrahamse-Testroote MCJ; Doorduijn J; Alemayehu WG; van Oers MHJ
Article: BLOOD. 2014;123(19):2953-2959
Nordic MCL3 study: ⁹⁰Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
Kolstad A; Laurell A; Jerkeman M; Gronbaek K; Elonen E; Raty R; Pedersen LB; Loft A; Bogsrud TV; Kimby E; Hansen PB; Fagerli U-M; Nilsson-Ehle H; Lauritzsen GF; Lehmann AK; Sundstrom C; Karjalainen-Lindsberg M-L; Ralfkiaer E; Ehinger M; Delabie J; Bentzen H; Schildt J; Kostova-Aherdan K; Frederiksen H; Brown PDN; Geisler CH
Article: LEUKEMIA & LYMPHOMA. 2014;55(2):288-295
Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy
Wahlin BE; Sundstrom C; Sander B; Christensson B; Jeppsson-Ahlberg A; Hjalmarsson E; Holte H; Ostenstad B; Brown PD; Smeland EB; Kimby E
Article: MEDICAL ONCOLOGY. 2013;30(4):762
High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse
Machaczka M; Johansson J-E; Remberger M; Hallbook H; Lazarevic VL; Wahlin BE; Omar H; Wahlin A; Juliusson G; Kimby E; Hagglund H
Article: ANNALS OF ONCOLOGY. 2013;24:vi155-vi159
Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Buske C; Leblond V; Dimopoulos M; Kimby E; Jaeger U; Dreyling M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(13):1624-1630
Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozak T; Dreger P; Uddin R; de Elvira CR; Goldstone AH
Article: LEUKEMIA & LYMPHOMA. 2013;54(4):790-793
Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis
Vojdeman FJ; Jurlander J; van't Veer M; Itala-Remes M; Kimby E; Tjonnfjord GE; Walewski J; Kozak T; Polliack A; Montagna M; Regazzi M; Kirkby N; van Oers M; Geisler CH
Article: ANNALS OF ONCOLOGY. 2013;24(3):561-576
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
Ghielmini M; Vitolo U; Kimby E; Montoto S; Walewski J; Pfreundschuh M; Federico M; Hoskin P; McNamara C; Caligaris-Cappio F; Stilgenbauer S; Marcus R; Trneny M; Dreger P; Montserrat E; Dreyling M
Article: SCIENTIFIC REPORTS. 2013;3:1400
SOXC transcription factors in mantle cell lymphoma: the role of promoter methylation in SOX11 expression
Wasik AM; Lord M; Wang X; Zong F; Andersson P; Kimby E; Christensson B; Karimi M; Sander B
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2013;160(2):171-176
Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop
Owen RG; Kyle RA; Stone MJ; Rawstron AC; Leblond V; Merlini G; Garcia-Sanz R; Ocio EM; Morra E; Morel P; Anderson KC; Patterson CJ; Munshi NC; Tedeschi A; Joshua DE; Kastritis E; Terpos E; Ghobrial IM; Leleu X; Gertz MA; Ansell SM; Morice WG; Kimby E; Treon SP
Article: LEUKEMIA & LYMPHOMA. 2012;53(9):1699-1705
Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
Machaczka M; Johansson J-E; Remberger M; Hallbook H; Malm C; Lazarevic VL; Wahlin A; Omar H; Juliusson G; Kimby E; Hagglund H
Article: CURRENT HEMATOLOGIC MALIGNANCY REPORTS. 2012;7(3):221-227
Biological Therapy Doublets: Pairing Rituximab with Interferon, Lenalidomide, and Other Biological Agents in Patients with Follicular Lymphoma
Kimby E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2012;158(3):355-362
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
Geisler CH; Kolstad A; Laurell A; Jerkeman M; Raty R; Andersen NS; Pedersen LB; Eriksson M; Nordstrom M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundstrom C; Delabie J; Karjalainen-Lindsberg M-L; Brown P; Elonen E
Article: BLOOD. 2012;119(18):4215-4223
Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma
Nygren L; Wennerholm SB; Klimkowska M; Christensson B; Kimby E; Sander B
Article: LEUKEMIA & LYMPHOMA. 2012;53(3):417-423
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
Wendtner C-M; Hillmen P; Mahadevan D; Buehler A; Uharek L; Coutre S; Frankfurt O; Bloor A; Bosch F; Furman RR; Kimby E; Gribben JG; Gobbi M; Dreisbach L; Hurd DD; Sekeres MA; Ferrajoli A; Shah S; Zhang J; Moutouh-de Parseval L; Hallek M; Heerema NA; Stilgenbauer S; Chanan-Khan AA
Article: LEUKEMIA & LYMPHOMA. 2012;53(1):139-144
Up-regulated estrogen receptor β2 in chronic lymphocytic leukemia
Yakimchuk K; Norin S; Kimby E; Hagglund H; Warner M; Gustafsson J-A
Article: BLOOD CANCER JOURNAL. 2012;2(1):e52
Entourage: the immune microenvironment following follicular lymphoma
Wahlin BE; Sander B; Christensson B; Ostenstad B; Holte H; Brown PD; Sundstrom C; Kimby E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2012;156(2):225-233
Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
Wahlin BE; Yri OE; Kimby E; Holte H; Delabie J; Smeland EB; Sundstrom C; Christensson B; Sander B
Article: CELL DEATH & DISEASE. 2011;2(11):e225
WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells
Wasik AM; Almestrand S; Wang X; Hultenby K; Dackland A-L; Andersson P; Kimby E; Christensson B; Sander B
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2011;86(8):709-710
Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: A retrospective study
Lazarevic VL; Remberger M; Hagglund H; Hallbook H; Juliusson G; Kimby E; Malm C; Wahlin A; Omar H; Johansson J-E
Article: CLINICAL CANCER RESEARCH. 2011;17(12):4136-4144
T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
Wahlin BE; Sundstrom C; Holte H; Hagberg H; Erlanson M; Nilsson-Ehle H; Linden O; Nordstrom M; Ostenstad B; Geisler CH; Brown PDN; Lehtinen T; Maisenholder M; Tierens AM; Sander B; Christensson B; Kimby E
Article: BONE MARROW TRANSPLANTATION. 2011;46(6):870-875
Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder
Johansson J-E; Remberger M; Lazarevic VL; Hallbook H; Wahlin A; Kimby E; Juliusson G; Omar H; Hagglund H
Article: GENES CHROMOSOMES & CANCER. 2011;50(2):113-121
High-Resolution Genomic Screening in Mantle Cell Lymphoma-Specific Changes Correlate with Genomic Complexity, the Proliferation Signature and Survival
Halldorsdottir AM; Sander B; Goransson H; Isaksson A; Kimby E; Mansouri M; Rosenquist R; Ehrencrona H
Article: LEUKEMIA & LYMPHOMA. 2011;52(1):69-71
Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden
Lazarevic VL; Hagglund H; Remberger M; Wahlin A; Hallbook H; Juliusson G; Kimby E; Malm C; Omar H; Johansson J-E
Article: PLOS ONE. 2010;5(11):e14085
Gene Expression Profiling and Chromatin Immunoprecipitation Identify DBN1, SETMAR and HIG2 as Direct Targets of SOX11 in Mantle Cell Lymphoma
Wang X; Bjoerklund S; Wasik AM; Grandien A; Andersson P; Kimby E; Dahlman-Wright K; Zhao C; Christensson B; Sander B
Article: MEDICAL ONCOLOGY. 2010;27(3):820-825
Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia
Norin S; Kimby E; Lundin J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(13):2246-2252
BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study
van Oers MHJ; Tonnissen E; Van Glabbeke M; Giurgea L; Jansen JH; Klasa R; Marcus RE; Wolf M; Kimby E; Vranovsky A; Holte H; Hagenbeek A; van der Reijden BA
Article: LEUKEMIA RESEARCH. 2010;34(3):335-339
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia
Kaderi MA; Mansouri M; Zainuddin N; Cahill N; Gunnarsson R; Jansson M; Kimby E; Aleskog A; Lundin J; Glimelius B; Melbye M; Juliusson G; Jurlander J; Rosenquist R
Article: BLOOD. 2010;115(8):1530-1533
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Geisler CH; Kolstad A; Laurell A; Raty R; Jerkeman M; Eriksson M; Nordstrom M; Kimby E; Boesen AM; Nilsson-Ehle H; Kuittinen O; Lauritzsen GF; Ralfkiaer E; Ehinger M; Sundstrom C; Delabie J; Karjalainen-Lindsberg M-L; Brown P; Elonen E
Article: CLINICAL CANCER RESEARCH. 2010;16(2):637-650
A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1-Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages
Wahlin BE; Aggarwal M; Montes-Moreno S; Francisco Gonzalez L; Roncador G; Sanchez-Verde L; Christensson B; Sander B; Kimby E
Article: LEUKEMIA & LYMPHOMA. 2009;50(10):1699-1708
Functional signatures identified in B-cell non-Hodgkin lymphoma profiles
Aggarwal M; Sanchez-Beato M; Gomez-Lopez G; Al-Shahrour F; Martinez N; Rodriguez A; Ruiz-Ballesteros E; Camacho FI; Perez-Rosado A; de la Cueva P; Artiga MJ; Pisano DG; Kimby E; Dopazo J; Villuendas R; Piris MA
Article: IMMUNOTHERAPY. 2009;1(5):753-764
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Bjorkstrom NK; Soderdahl G; Cederlund K; Kimby E; Aschan J; Ringden O; Ljunggren H-G; Dilber MS
Article: BLOOD. 2009;113(16):3673-3678
Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia
Treon SP; Branagan AR; Ioakimidis L; Soumerai JD; Patterson CJ; Turnbull B; Wasi P; Emmanouilides C; Frankel SR; Lister A; Morel P; Matous J; Gregory SA; Kimby E
Article: MODERN PATHOLOGY. 2009;22(2):206-215
TCL1A expression delineates biological and clinical variability in B-cell lymphoma
Aggarwal M; Villuendas R; Gomez G; Rodriguez-Pinilla SM; Sanchez-Beato M; Alvarez D; Martinez N; Rodriguez A; Castillo ME; Camacho FI; Montes-Moreno S; Garcia-Marco JA; Kimby E; Pisano DG; Piris MA
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;144(1):78-85
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia
Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Article: BLOOD. 2008;112(7):2687-2693
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Geisler CH; Kolstad A; Laurell A; Andersen NS; Pedersen LB; Jerkeman M; Eriksson M; Nordstrom M; Kimby E; Boesen AM; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Akerman M; Ehinger M; Sundstrom C; Langholm R; Delabie J; Karjalainen-Lindsberg M-L; Brown P; Elonen E
Article: INTERNATIONAL JOURNAL OF CANCER. 2008;123(5):1025-1033
Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation
Gustafsson K; Wang X; Severa D; Eriksson M; Kimby E; Merup M; Christensson B; Flygare J; Sander B
Article: INVESTIGATIONAL NEW DRUGS. 2008;26(2):139-149
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
Jensen M; Engert A; Weissinger F; Knauf W; Kimby E; Poynton C; Oliff IA; Rummel MJ; Oesterborg A
Article: ACTA ONCOLOGICA. 2008;47(6):1029-1036
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Article: MEDICAL ONCOLOGY. 2008;25(4):374-379
Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis
Tesfa D; Gelius T; Sander B; Kimby E; Fadeel B; Palmblad J; Hagglund H
Article: LEUKEMIA & LYMPHOMA. 2008;49(1):102-112
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a:: A randomized phase II study from the Nordic Lymphoma Group
Kimby E; Jurlander J; Geisler C; Hagberg H; Holte H; Lehtinen T; Oestenstad B; Hansen M; Oesterborg A; Linden O; Sundstroem C
Article: LEUKEMIA & LYMPHOMA. 2007;48(7):1344-1352
Characterization of genetic changes in MCL by interphase FISH on tissue sections
Sander B; Wallblom A; Ekroth A; Porwit A; Kimby E
Article: CLINICAL CANCER RESEARCH. 2007;13(2):388-397
CD8+T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma
Wahlin BE; Sander B; Christensson B; Kimby E
Article: BLOOD. 2006;108(10):3295-3301
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
van Oers MHJ; Klasa R; Marcus RE; Wolf M; Kimby E; Gascoyne RD; Jack A; van't Veer M; Vranovsky A; Holte H; van Glabbeke M; Teodorovic I; Rozewicz C; Hagenbeek A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2006;77(3):203-209
Portal vein thrombosis is a common complication following splenectomy in patients with malignant haematological diseases
Svensson M; Wiren M; Kimby E; Hagglund H
Article: CLINICAL LYMPHOMA AND MYELOMA. 2006;6(5):380-383
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia
Kimby E; Treon SP; Anagnostopoulos A; Dimopoulos M; Garcia-Sanz R; Gertz MA; Johnson S; LeBlond V; Fermand J-P; Maloney DG; Merlini G; Morel P; Morra E; Nichols G; Ocio EM; Owen R; Stone M; Blade J
Article: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES. 2006;27(1):54-61
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies
Xie HJ; Griskevicius L; Ståhle L; Hassan Z; Yasar Ü; Rane A; Broberg U; Kimby E; Hassan M
Article: FEBS LETTERS. 2005;579(30):6885-6889
Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma
Flygare J; Gustafsson K; Kimby E; Christensson B; Sander B
Article: INTERNATIONAL JOURNAL OF CANCER. 2005;117(3):418-430
Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1
Sander B; Flygare J; Porwit-MacDonald A; Smith CIE; Emanuelsson E; Kimby E; Liden J; Christensson B
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2005;75(3):206-211
The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma
Afsharian P; Möllgård L; Hassan Z; Xie HJ; Kimby E; Hassan M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(3):474-481
Polymorphisms in FcγRIIIA (CD 16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia
Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
Article: ANNALS OF ONCOLOGY. 2005;16(1):132-138
Extended rituximab therapy in Waldenstrom's macroglobulinemia
Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR
Article: MEDICAL ONCOLOGY. 2005;22(3):291-302
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL) comparison of indolent and progressive disease
Kiaii S; Choudhury A; Mozaffari F; Kimby E; Österborg A; Mellstedt M
Article: BLOOD. 2004;104(4):948-955
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
Hale G; Rebello P; Brettman LR; Fegan C; Kennedy B; Kimby E; Leach M; Lundin J; Mellstedt H; Moreton P; Rawstron AC; Waldmann H; Osterborg A; Hillmen P
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2004;72(4):292-295
Safety of rituximab therapy during the first trimester of pregnancy: a case history
Kimby E; Sverrisdottir A; Elinder G
Article: LEUKEMIA. 2004;18(3):484-490
Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Österborg A; Mellstedt H
Article: MEDICAL ONCOLOGY. 2004;21(3):273-284
Posttransplant lymphoma -: A single-center experience of 500 liver transplantations
Norin S; Kimby E; Ericzon BG; Christensson B; Sander B; Söderdahl G; Häggland H
Article: HAEMATOLOGICA. 2003;88(11):1272-1278
Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation
Schetelig J; Fetscher S; Reichle A; Berdel WE; Beguin Y; Brunet S; Caballero D; Majolino I; Hagberg H; Johnsen HE; Kimby E; Montserrat E; Stewart D; Copplestone A; Rösler W; Pavel J; Kingreen D; Siegert W
Article: LEUKEMIA. 2003;17(10):1973-1980
Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
Article: LEUKEMIA. 2003;17(9):1880-1890
High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma
Islam TC; Asplund AC; Lindvall JM; Nygren L; Liden J; Kimby E; Christensson B; Smith CIE; Sander B
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2002;69(3):129-134
Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia:: results from a Nordic multicentre study
Itälä M; Geisler CH; Kimby E; Juvonen E; Tjonnfjord G; Karlsson K; Remes K
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;118(3):748-754
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia
Hallböök H; Simonsson B; Ahlgren T; Björkholm M; Carneskog J; Grimfors G; Hast R; Karlsson K; Kimby E; Lerner R; Linder O; Linderholm M; Löfvenberg E; Malm C; Nilsson PG; Paul C; Stenke L; Stockelberg D; Tidefelt U; Turesson I; Uden-Blome AM; Vilen L; Wahlin A; Winquist I; Smedmyr B
Article: BLOOD. 2002;100(3):768-773
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Österborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;116(3):538-548
Oral cladribine for B-cell chronic lymphocytic leukaemia:: Report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients
Karlsson K; Strömberg M; Liliemark J; Delannoy A; Johnson SAN; Porwit A; Kimby E; Lärfars G; Cristiansen I; Nilsson G; Celsing F; Sundström G; Luthman M; Tidefelt U; Wallvik J; Juliusson G
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2002;68(3):127-134
Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course
Hjalmar V; Hast R; Kimby E
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2001;31(12):3469-3474
Both normal and leukemic B lymphocytes express multiple isoforms of the human Aiolos gene
Liippo J; Nera KP; Veistinen E; Lähdesmäki A; Postila V; Kimby E; Riikonen P; Hammarström L; Pelkonen J; Lassila O
Article: JOURNAL OF IMMUNOTHERAPY. 2001;24(3):272-279
CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.
Treon SP; Agus DB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
Article: JOURNAL OF IMMUNOTHERAPY. 2001;24(3):272-279
CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
Article: LEUKEMIA RESEARCH. 2001;25(3):267-270
High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD
Lindahl J; Kimby E; Björkstrand B; Christensson B; Hellström-Lindberg E
Article: ACTA ONCOLOGICA. 2001;40(2-3):135-154
The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types -: Summary and conclusions
Glimelius B; Bergh J; Brandt L; Brorsson B; Gunnars B; Hafström L; Haglund U; Högberg T; Janunger KG; Jönsson PE; Karlsson G; Kimby E; Lamnevik G; Nilsson S; Permert J; Ragnhammar P; Sörenson S; Nygren P
Article: HAEMATOLOGICA. 2001;86(2):174-180
Sequential fluorescence in situ hybridization analyses for trisomy 12 in chronic leukemic B-cell disorders
Hjalmar V; Hast R; Kimby E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;112(1):155-160
Interleukin 4 therapy for patients with chronic lymphocytic leukaemia:: a phase I/II study
Lundin J; Kimby E; Bergmann L; Karakas T; Mellstedt H; Österborg A
Article: LEUKEMIA & LYMPHOMA. 2000;37(5-6):571-576
Atypical lymphocytes in B-cell chronic lymphocytic leukemia and trisomy 12 studied by conventional staining combined with fluorescence in situ hybridization
Hjalmar V; Kimby E; Matutes E; Sundström C; Wallvik J; Hast R
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;108(3):595-601
Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL):: a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP)
Michallet M; Thiébaut A; Dreger P; Remes K; Milpied N; Santini G; Hamon M; Björkstrand B; Kimby E; Belhabri A; Tanguy ML; Apperley JF
Article: LEUKEMIA. 2000;14(2):247-254
Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease
Mattsson J; Uzunel M; Remberger M; Ljungman P; Kimby E; Ringdén O; Zetterquist H
Article: BLOOD. 1999;94(3):1063-1069
Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia:: Major perturbations are preferentially seen within the CD4 T-Cell subset
Rezvany MR; Jeddi-Tehrani M; Österborg A; Kimby E; Wigzell H; Mellstedt H
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 1999;91(10):861-868
Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.
Article: HAEMATOLOGICA. 1998;83(7):602-609
Trisomy 12 and lymphoplasmacytoid lymphocytes in chronic leukemic B-cell disorders
Hjalmar V; Kimby E; Matutes E; Sundström C; Jacobsson B; Arvidsson I; Hast R
Article: MEDICAL ONCOLOGY. 1996;13(4):185-194
Treatment of aggressive non-Hodgkin's lymphoma in adults - Are we doing any better?
Hagberg H; Kimby E
Article: JOURNAL OF CLINICAL ONCOLOGY. 1996;14(7):2160-2166
Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia
Juliusson G; Christiansen I; Hansen MM; Johnson S; Kimby E; ElmhornRosenborg A; Liliemark J
Article: MEDICAL ONCOLOGY. 1996;13(2):95-101
Chronic lymphocytic leukaemia at a country hospital in southern Sweden
Hjalmar V; Carlsson M; Kimby E
Article: LANCET. 1996;347(9013):1432-1438
Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia
Fenaux P; Binet JL; Leporrier M; Travade P; Piguet H; Linassier C; Desablens B; Dreyfus B; Brizard CP; Murgue B; Russet T; Souteyrand P; Johnson S; Phillips MJ; Hiddemann W; Smith A; Roath S; Loffler H; Bjorkholm M; Osby E; Emmerich B; Coiffier B; Thiel E; Knauf W; Juliusson G; Marcus R; Prentice AG; Copplestone JA; Freund M; Milligan PW; Winfield D; Yin J; Hellriegel KP; Hossfeld DK; Kimby E; Burnett AK; Lister TA; Lucie N; Kanz L; Lerner R; Lindemalm C; Child A; Hamblin T; Oscier D; Smith JG; Singer RJ; Parker A; Whittaker J; Wyld P; Smith AG
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1995;55(1):19-23
MITOXANTRONE, ETOPOSIDE AND ARA-C VS DOXORUBICIN-DNA, ARA-C, THIOGUANINE, VINCRISTINE AND PREDNISOLONE IN THE TREATMENT OF PATIENTS WITH ACUTE MYELOCYTIC-LEUKEMIA - A RANDOMIZED COMPARISON
BJORKHOLM M; LILIEMARK J; GAHRTON G; GRIMFORS G; GRUBER A; HAST R; JULIUSSON G; JARNMARK M; KILLANDER A; KIMBY E; LERNER R; LJUNGMAN P; LONNQVIST B; PALMBLAD J; PAUL C; PETTERSON C; SIMONSSON B; STALFELT AM; STENKE L; SUNDSTROM C; TIDEFELT U; UDEN AM; OBERG G; OST A
Article: JOURNAL OF INTERNAL MEDICINE. 1995;237(1):27-33
ENDOTOXEMIA AND INFLAMMATORY MEDIATORS IN FEBRILE PATIENTS WITH HEMATOLOGICAL DISEASE
GUNTHER G; GARDLUND B; HAST R; KIMBY E; NORDIN M; WRETLIND B
Show more

All other publications

Letter: HEMASPHERE. 2020;4(6):e481
Double Hit Lymphoma Diagnosis and Treatment in Europe-A Cross-Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG)
Aurer I; Dreyling M; Federico M; Tilly H; Linton K; Kimby E; Chamuleau MED; Kersten MJ
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;190(4):e258-e261
Immunomodulatory drugs may overcome the negative prognostic role of active Th17 axis in follicular lymphoma: evidence from the SAKK35/10 trial
Menter T; Hayoz S; Zucca E; Kimby E; Dirnhofer S; Tzankov A
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2020;95(2):E36-E38
Increasing prevalence of chronic lymphocytic leukemia with an estimated future rise: A nationwide population-based study
Mattsson M; Sandin F; Kimby E; Hoeglund M; Glimelius I
Letter: HAEMATOLOGICA. 2019;104(10):e460-e464
A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy
Steen CB; Leich E; Myklebust JH; Lockmer S; Wise JF; Wahlin BE; Ostenstad B; Liestol K; Kimby E; Rosenwald A; Smeland EB; Holte H; Lingjaerde OC; Brodtkorb M
Letter: ACTA ONCOLOGICA. 2019;58(6):824-827
Incidence and inheritance of hyperphosphorylated paratarg-7 in patients with Waldenstrom's macroglobulinaemia in Sweden
Brandefors L; Lindh J; Preuss K-D; Fadle N; Pfreundschuh M; Kimby E
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(9):759-760
Is Longer Progression-Free Survival a Goal Worth Pursuing in Follicular Lymphoma? Reply
Lockmer S; Ostenstad B; Hagberg H; Holte H; Wahlin BE; Wader KF; Smedby KE; Brown P; Kimby E
Review: ANNALS OF ONCOLOGY. 2018;29(2):332-340
Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas
Karmali R; Kimby E; Ghielmini M; Flinn IW; Gordon LI; Zucca E
Published conference paper: JOURNAL OF INTERNAL MEDICINE. 2017;282(5):415-428
Targeting of B-cell receptor signalling in B-cell malignancies
Jerkeman M; Hallek M; Dreyling M; Thieblemont C; Kimby E; Staudt L
Corrigendum: LEUKEMIA RESEARCH. 2017;57:127
Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS) (Vol 13, 31, 1989)
Garcia C; Rosen A; Kimby E; Aguilar-Santelises M; Jondal M; Bjorkhilm M; Holm G; Mellstedt H
Editorial comment: HAEMATOLOGICA. 2017;102(6):972-975
Unmet needs in the scientific approach to older patients with lymphoma
Bron D; Aurer I; Andre MPE; Bonnet C; Caballero D; Falandry C; Kimby E; Soubeyran P; Zucca E; Bosly A; Coiffier B
Published conference paper: JOURNAL OF CLINICAL ONCOLOGY. 2017;35(5):552-560
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials
Shi Q; Flowers CR; Hiddemann W; Marcus R; Herold M; Hagenbeek A; Kimby E; Hochster H; Vitolo U; Peterson BA; Gyan E; Ghielmini M; Nielsen T; De Bedout S; Fu T; Valente N; Fowler NH; Hoster E; Ladetto M; Morschhauser F; Zucca E; Salles G; Sargent DJ
Review: BLOOD. 2016;128(10):1321-1328
Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia
Leblond V; Kastritis E; Advani R; Ansell SM; Buske C; Castillo JJ; Garcia-Sanz R; Gertz M; Kimby E; Kyriakou C; Merlini G; Minnema MC; Morel P; Morra E; Rummel M; Wechalekar A; Patterson CJ; Treon SP; Dimopoulos MA
Review: LEUKEMIA & LYMPHOMA. 2016;57(4):766-782
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update
Cheson BD; Brugger W; Damaj G; Dreyling M; Kahl B; Kimby E; Ogura M; Weidmann E; Wendtner C-M; Zinzani PL
Review: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2015;82(3):208-217
Targets for Ibrutinib Beyond B Cell Malignancies
Berglof A; Hamasy A; Meinke S; Palma M; Krstic A; Mansson R; Kimby E; Osterborg A; Smith CIE
Editorial comment: BLOOD. 2015;125(6):892-893
Serum cytokines in follicular lymphoma
Kimby E
Review: BLOOD. 2014;124(9):1404-1411
Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus
Dimopoulos MA; Kastritis E; Owen RG; Kyle RA; Landgren O; Morra E; Leleu X; Garcia-Sanz R; Munshi N; Anderson KC; Terpos E; Ghobrial IM; Morel P; Maloney D; Rummel M; Leblond V; Advani RH; Gertz MA; Kyriakou C; Thomas SK; Barlogie B; Gregory SA; Kimby E; Merlini G; Treon SP
Editorial comment: JOURNAL OF INTERNAL MEDICINE. 2013;274(6):541-546
Searching the haematology and inflammation archives of Journal of Internal Medicine
Palmblad J; Kimby E
Review: HAEMATOLOGICA. 2013;98(7):1014-1021
Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party
Montoto S; Corradini P; Dreyling M; Ghielmini M; Kimby E; Lopez-Guillermo A; Mackinnon S; Marcus RE; Salles G; Schouten HC; Sureda A; Dreger P
Review: EXPERIMENTAL ONCOLOGY. 2012;34(4):384-385
Leukemic phase of B-lineage NHL.
Kimby E
Corrigendum: BRITISH JOURNAL OF HAEMATOLOGY. 2012;158(6):815-816
Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC Plus autologous stem-cell support: still very long survival but late relapses do occur (vol 158, pg 355, 2012)
Geisler CH; Kolstad A; Laurell A; Jerkeman M; Raty R; Andersen NS; Pedersen LB; Eriksson M; Nordstrom M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundstrom C; Delabie J; Karjalainen-Lindsberg M-L; Brown P; Elonen E
Letter: LEUKEMIA & LYMPHOMA. 2012;53(3):503-505
Long-term survival after allogeneic stem cell transplant for relapsed large B cell lymphomas: a retrospective study
Lazarevic V; Remberger M; Hagglund H; Juliusson G; Omar H; Halbook H; Kimby E; Malm C; Wahlin A; Johansson J-E
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2012;156(3):407-409
Better response with conjugate vaccine than with polysaccaride vaccine 12 months after rituximab treatment in lymphoma patients
Svensson M; Dahlin U; Kimby E
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(2):S196
NORDIC MCL2 TRIAL OF 1ST-LINE INTENSIVE IMMUNOCHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA: STILL ENCOURAGING RESULTS AFTER MEDIAN 51/2 YEARS OBSERVATION TIME
Geisler CH; Kolstad A; Laurell A; Raty R; Jerkeman M; Eriksson M; Nordstrom M; Kimby E; Bentzen HEN; Nilsson-Ehle H; Kuittinen O; Lauritzsen GF; Ralfkiaer E; Ehinger M; Sundstrom C; Delabie J; Karjalainen-Lindsberg M-L; Pedersen LB; Andersen NS; Brown PDN; Elonen E
Editorial comment: CLINICAL LYMPHOMA AND MYELOMA. 2009;9(1):10-15
Advances in the Biology and Treatment of Waldenstrom's Macroglobulinemia: A Report from the 5th International Workshop on Waldenstrom's Macroglobulinemia, Stockholm, Sweden Introduction
Treon SP; Patterson CJ; Kimby E; Stone MJ
Review: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(1):120-126
Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia
Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; LeBlond V; Fermand J-P; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
Meeting abstract: BLOOD. 2007;110(11):199A
Interim results of a phase I/II study of ocrelizumab, a new humanised Anti-CD20 antibody in patients with relapsed/refractory follicular non-hodgkin's lymphoma
Morschhauser F; Marlton P; Vitolo U; Linden O; Seymour J; Crump M; Coiffier B; Pulsoni A; Belch A; Lerch E; Kimby E; Arnljots K; Wassner E; Mendila M
Meeting abstract: VALUE IN HEALTH. 2007;10(6):A331
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular non-Hodgkin's lymphoma in Sweden
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lunckvist J
Review: CURRENT HEMATOLOGIC MALIGNANCY REPORTS. 2007;2(4):242-248
Management of advanced-stage peripheral T-cell lymphomas.
Kimby E
Published conference paper: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2007;5(5):438-439
Therapy for patients with follicular lymphoma
Kimby E
Review: LEUKEMIA. 2007;21(1):12-17
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
Dreger P; Corradini P; Kimby E; Michallet M; Milligan D; Schetelig J; Wiktor-Jedrzejczak W; Niederwieser D; Hallek M; Montserrat E
Letter: LEUKEMIA. 2006;20(12):2204-2007
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia:: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation
Karlsson C; Norin S; Kimby E; Sander B; MacDonald AP; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Review: BLOOD. 2006;107(9):3442-3446
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia
Treon SP; Gertz MA; Dimopoulos M; Anagnostopoulos A; Blade J; Branagan AR; Garcia-Sanz R; Johnson S; Kimby E; LeBlond V; Fermand JP; Maloney DG; Merlini G; Morel P; Morra E; Nichols G; Ocio EM; Owen R; Stone MJ
Review: SEMINARS IN ONCOLOGY. 2006;33(2):S29-S35
Strategies in the management of alemtuzumab-related side effects
Osterborg A; Karlsson C; Lundin J; Kimby E; Mellstedt H
Review: CANCER TREATMENT REVIEWS. 2005;31(6):456-473
Tolerability and safety of rituximab (MabThera®)
Kimby E
Meeting abstract: BLOOD. 2004;104(11):215A
Combination therapy with rituximab and fludarabine in Waldenstrom's Macroglobulinemia.
Treon SP; Branagan A; Wasi P; Emmanouilides CA; Frankel SR; Lister A; Morel P; Matous J; Enschede SH; Kimby E
Meeting abstract: BLOOD. 2004;104(11):96B
Portal vein thrombosis a common complication following splenectomy in adults patients with CLL or myeloproliferative disease.
Svensson M; Wiren M; Kimby E; Hagglund H
Meeting abstract: BLOOD. 2004;104(11):889A
T-cells present in tumour tissue may affect the outcome of follicular lymphoma
Wahlin BE; Kimby E; Sander B; Christensson B
Review: SEMINARS IN ONCOLOGY. 2003;30(2):248-252
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations
Treon SP; Kelliher A; Keele B; Frankel S; Emmanouilides C; Kimby E; Schlossman R; Mitsiades N; Mitsiades C; Preffer F; Anderson KC
Review: SEMINARS IN ONCOLOGY. 2003;30(2):127-131
Uniform response criteria in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia
Weber D; Treon SP; Emmanouilides C; Branagan AR; Byrd JC; Bladé J; Kimby E
Published conference paper: ANTI-CANCER DRUGS. 2002;13:S11-S17
Rituximab therapy for indolent non-Hodgkin's lymphoma
Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
Published conference paper: SEMINARS IN ONCOLOGY. 2002;29(2):7-10
Beyond immunochemotherapy:: Combinations of rituximab with cytokines interferon-α2a and granulocyte-macrophage colony stimulating factor
Kimby E
Review: ACTA ONCOLOGICA. 2001;40(2-3):231-252
A systematic overview of chemotherapy effects in acute myeloid leukaemia
Kimby E; Nygren P; Glimelius B
Review: ACTA ONCOLOGICA. 2001;40(2-3):224-230
A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia
Kimby E; Brandt L; Nygren P; Glimelius B
Review: ACTA ONCOLOGICA. 2001;40(2-3):213-223
A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma
Brandt L; Kimby E; Nygren P; Glimelius B
Review: ACTA ONCOLOGICA. 2001;40(2-3):198-212
A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma
Kimby E; Brandt L; Nygren P; Glimelius B
Review: ACTA ONCOLOGICA. 2001;40(2-3):185-197
A systematic overview of chemotherapy effects in Hodgkin's disease
Brandt L; Kimby E; Nygren P; Glimelius B
Review: LEUKEMIA & LYMPHOMA. 1997;27(5-6):429-438
Histamine and interleukin-2 in acute myelogenous leukemia
Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
Show more

Employments

Affiliated to Teaching/Tutoring, Department of Medicine, Huddinge, Karolinska Institutet, 2023-2026

Degrees and Education

Docent, 1994

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI